Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Moerman

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
The Lancet. Oncology|March 1, 2008
Are gene signatures better than traditional clinical factors?Patrick Neven, Vanya Van Belle, Olivier Brouckaert, et al.
Human Mutation|October 6, 2009
Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathwaysKarin Leunen, Olivier Gevaert, Anneleen Daemen, et al.
European Journal of Medical Genetics|June 28, 2014
Homozygous loss-of-function mutation in ALMS1 causes the lethal disorder mitogenic cardiomyopathy in two siblingsJacoba J Louw, Anniek Corveleyn, Yaojuan Jia, et al.
Anticancer Research|September 12, 2013
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcomaAn Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 8, 2011
Evolution in endometrial cancer: evidence from an immunohistochemical studyIngrid Vandenput, Jone Trovik, Karin Leunen, et al.
Anticancer Research|December 11, 2013
Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trialAn Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, et al.
Clinical Breast Cancer|October 9, 2012
Sentinel lymph node involvement in ductal carcinoma in-situ of the breast: two different causesOlivier Brouckaert, Anneleen Reynders, Kathleen Vanderstappen, et al.
Gynecologic Oncology|June 16, 2004
Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcomaFrederic Amant, Katrien Schurmans, Edwin Steenkiste, et al.
Gynecologic Oncology|June 24, 2005
Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancerFrederic Amant, Isabelle Cadron, Luca Fuso, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2017
Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancerKatrijn Michielsen, Raphaëla Dresen, Ragna Vanslembrouck, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|March 1, 2008
Are gene signatures better than traditional clinical factors?Patrick Neven, Vanya Van Belle, Olivier Brouckaert, et al.
Human Mutation|October 6, 2009
Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathwaysKarin Leunen, Olivier Gevaert, Anneleen Daemen, et al.
European Journal of Medical Genetics|June 28, 2014
Homozygous loss-of-function mutation in ALMS1 causes the lethal disorder mitogenic cardiomyopathy in two siblingsJacoba J Louw, Anniek Corveleyn, Yaojuan Jia, et al.
Anticancer Research|September 12, 2013
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcomaAn Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 8, 2011
Evolution in endometrial cancer: evidence from an immunohistochemical studyIngrid Vandenput, Jone Trovik, Karin Leunen, et al.
Anticancer Research|December 11, 2013
Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trialAn Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, et al.
Clinical Breast Cancer|October 9, 2012
Sentinel lymph node involvement in ductal carcinoma in-situ of the breast: two different causesOlivier Brouckaert, Anneleen Reynders, Kathleen Vanderstappen, et al.
Gynecologic Oncology|June 16, 2004
Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcomaFrederic Amant, Katrien Schurmans, Edwin Steenkiste, et al.
Gynecologic Oncology|June 24, 2005
Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancerFrederic Amant, Isabelle Cadron, Luca Fuso, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2017
Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancerKatrijn Michielsen, Raphaëla Dresen, Ragna Vanslembrouck, et al.
Pageof 10